Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
Latest Information Update: 17 Oct 2023
At a glance
- Drugs Tapinarof (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Dermavant Sciences
Most Recent Events
- 16 Oct 2023 According to a Dermavant Sciences media release, results will be presented at the 2023 Fall Clinical Dermatology Conference, to be held October 19-22 in Las Vegas, NV
- 12 Jan 2023 According to a Dermavant Sciences media release, this study will be presented at the 20th Annual Winter Clinical Dermatology Conference.
- 08 Nov 2022 According Dermavant Sciences media release, company anticipates presenting the full data set from this study at a future medical meeting.